OpenAI acquires startup Orchestra Bio to beef up its biotech business

OpenAI announced on Tuesday its acquisition of Orchestra Bio, a four-year-old AI biotech software startup. Although financial terms were not disclosed, Orchestra reportedly raised around $20 million as of 2025 from investors such as Andreessen Horowitz, Atria, and 8VC. Orchestra specializes in AI agents that assist biotech companies with drug discovery operations, including financial tracking and clinical trial scheduling. OpenAI plans to integrate Orchestra's team and technology into Rosalind, its AI model for life sciences research, and the related Rosalind Workbench tool, which helps researchers plan experiments and analyze results. Rosalind already counts major pharmaceutical companies like Moderna and Novo Nordisk as customers. This acquisition exemplifies how major AI labs like OpenAI and Anthropic are expanding into software for large industries such as pharma, and it highlights the startup ecosystem's fear of being outcompeted by such labs—though in this case, Orchestra is being absorbed rather than displaced.

(Source：TechCrunch)